UBS Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $288
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Eliana Merle maintains a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raises the price target from $253 to $288.
June 28, 2024 | 2:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Eliana Merle maintains a Buy rating on Alnylam Pharmaceuticals and raises the price target from $253 to $288.
The raised price target and maintained Buy rating from a reputable analyst at UBS is likely to positively impact Alnylam Pharmaceuticals' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100